58 completed, 7 unknown, 2 terminated, 2 withdrawn. 69 Phase 2, 13 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 69 | Completed 58, Unknown 7, Terminated 2, Withdrawn 2 |
| Phase 3 | 13 | Completed 7, Unknown 6 |
| Phase 1 | 3 | Completed 3 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| COVID-19 Prophylaxis South Africa (COVER HCW) Nitazoxanide, Sofosbuvir/Daclatasvir - Covid19, SARS-CoV Infection | Phase 2 | Completed | University of Witwatersrand, South Africa | 1950 | 2020-12-08 | 2022-06-07 |
| Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Paracetamol, Artesunate-amodiaquine, Pyronaridine-artesunate - COVID-19 | Phase 2 | Completed | Shin Poong Pharmaceutical Co. Ltd. | 192 | 2020-09-03 | 2025-07-28 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients Sofosbuvir, Daclatasvir - Covid19 | Phase 2 / Phase 3 | Unknown | Tanta University | 100 | 2020-07-01 | 2020-12-03 |
| Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | Cairo University | 100 | 2020-07-01 | 2020-06-25 |
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Narlaprevir, Ritonavir, Sofosbuvir - Chronic Hepatitis c Genotype 1 | Phase 2 | Completed | R-Pharm | 85 | 2019-05-06 | 2022-10-31 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 2 | Unknown | Ginkgopharma CO., LTD | 36 | 2019-04-03 | 2019-10-01 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection Daclatasvir, Sofosbuvir - Hepatitis C, Chronic Hepatitis | Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2018-06-25 | 2021-04-20 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG - Hepatitis B | Phase 2 | Completed | University of Maryland, Baltimore | 21 | 2018-02-01 | 2021-09-20 |
| A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C | Phase 2 | Completed | University of Dundee | 129 | 2018-01-19 | 2021-11-18 |
| Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus Daclatasvir and sofosbuvir - Chronic HCV Infection | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2017-12-10 | 2023-03-06 |
| HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Sofosbuvir - Hepatitis E, Hepatitis Chronic Viral | Phase 2 | Completed | Hannover Medical School | 10 | 2017-12-07 | 2019-03-08 |
| Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome | Phase 2 / Phase 3 | Completed | Ain Shams University | 100 | 2017-12-01 | 2018-09-20 |
| Harvoni Treatment Porphyria Cutanea Tarda Harvoni - Porphyria Cutanea Tarda, Hepatitis C | Phase 2 | Completed | Wake Forest University Health Sciences | 23 | 2017-09-06 | 2023-07-03 |
| Phase 2 Study of Yimitasvir Phosphate Capsules SOF, DAG181 - Chronic HCV Infection | Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 129 | 2017-07-31 | 2020-03-18 |
| Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C KW-136, Sofosbuvir - Hepatitis C, Chronic | Phase 2 | Completed | Kawin Technology Share-holding Co., Ltd. | 110 | 2017-02-15 | 2018-01-31 |
Showing 20 of 69. Sign in to see all of them.
Hepatitis C (38) · Hepatitis C, Chronic (20) · Hepatitis (7) · COVID-19 (4) · Bronchiolitis Obliterans Syndrome (2) · Directly Observed Therapy (2) · Fibrosis (2) · Hepatitis, Chronic (2) · Carcinoma, Hepatocellular (1) · Digestive System Diseases (1) · Enterovirus Infections (1) · Flaviviridae Infections (1) · HIV Infections (1) · Hemophilia A (1) · Hepatitis A (1)
Gilead Sciences (17) · Bristol-Myers Squibb (5) · ANRS, Emerging Infectious Diseases (3) · Humanity and Health Research Centre (3) · AbbVie (2) · Ain Shams University (2) · Janssen Research & Development, LLC (2) · Johns Hopkins Bloomberg School of Public Health (2) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Sunshine Lake Pharma Co., Ltd. (2) · Tanta University (2) · Beni-Suef University (1) · Cairo University (1) · Drugs for Neglected Diseases (1)
United States (29) · Puerto Rico (10) · New Zealand (8) · China (7) · Egypt (7) · France (6) · Australia (5) · Spain (4) · Canada (3) · Germany (3) · Belgium (2) · India (2) · Malaysia (2) · Russia (2) · South Africa (2)
Robert H. Hyland, DPhil (5) · Robert H Hyland, DPhil (2) · Ahmed Cordie, lecturer (1) · Anuj Gaggar, MD/PhD (1) · Babacar Sylla (1) · Eric Bellissant (1) · Eric Cohen, MD (1) · Eric Rosenthal (1) · Francois Venter, PhD (1)
PMID 26596948, PMID 23281974, PMID 23499158, PMID 23499440, PMID 23982366, PMID 24209977, PMID 24262278, PMID 24428467, PMID 24983321, PMID 25078309, PMID 25261839, PMID 25304641, PMID 25364884, PMID 25591505, PMID 25622055, PMID 25733369, PMID 26187031, PMID 26261007, PMID 26521268, PMID 26551051, PMID 26551263, PMID 26595450, PMID 26612014, PMID 26691547, PMID 27367295, PMID 27770561, PMID 27790789, PMID 27878906, PMID 27896858, PMID 27917405, PMID 27943563, PMID 28543053, PMID 28719029, PMID 28935432, PMID 28971875, PMID 29077864, PMID 29193603, PMID 29274193, PMID 29310928, PMID 29439971, PMID 29473975, PMID 30598598, PMID 31222783, PMID 31300820, PMID 31399460, PMID 31520460, PMID 32166305, PMID 32270053, PMID 32367815, PMID 32531259
2015 (5), 2017 (3), 2014 (2), R01DA026727 (2), U54DK083909 (1)